Require Regulatory Scientist at UCB
UCB is a global biopharmaceutical company. We focus on discovering and developing innovative medicines and lateral solutions that can transform the everyday lives of people with severe diseases of the immune system – or the central nervous system. With more than 8500 people in approximately 40 countries, UCB offers an exciting working environment where initiative can flourish and those with a ‘can-do’ attitude can thrive. Scientific excellence, innovation, co-creation, lateral thinking, reinventing the way we do things…these are some of the key competencies we are constantly developing, and looking for, at UCB.
Post : Regulatory Scientist

Indian Institute of Chemical Technology, Hyderabad is a premier R&D Institute in India. The Institute had its origin as the Central Laboratories for Scientific & Industrial Research (CLSIR), established in 1944 by the then Government of Hyderabad State. After integration of Hyderabad State with the Indian Union, the laboratory expanded with its growing activities. The main building was formally opened by Pandit Jawaharlal Nehru, the then Prime Minister of India on January 2, 1954. In 1956, the Central Laboratories came under the aegis of the Council of Scientific & Industrial Research (CSIR), New Delhi and was renamed Regional Research Laboratory, Hyderabad (RRL-H).
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.
One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS), has the first and only approved treatment for spinal muscular atrophy (SMA) and is at the forefront of research into new medicines for neurological and neurodegenerative conditions. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options.
